Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer's disease

Experimental Eye Research

Volumn 106, Issue , 2013, Pages 5-13

  Michael, Ralph ^a   Rosandić, Jurja ^a   Montenegro, Gustavo A ^a   Lobato, Elvira ^a,b   Tresserra, Francisco ^c   Barraquer, Rafael I ^a   Vrensen, Gijs F J M ^d  

^a INSTITUT UNIVERSITARI BARRAQUER   (Spain)

^b HOSPITAL DR LUIS SÁNCHEZ BULNES   (Mexico)

^c INSTITUT UNIVERSITARI DEXEUS   (Spain)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Beta amyloid; Congo red and thioflavin staining; Cortical cataract; Immuno histochemistry

Indexed keywords

AMYLOID BETA PROTEIN; CONGO RED; EFEPRISTIN; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; CATARACT; CONTROLLED STUDY; CORNEA; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LENS; ORGAN DONOR; PRIORITY JOURNAL; STAINING; STEREOMICROSCOPY; VASCULAR AMYLOIDOSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CATARACT; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LENS CORTEX, CRYSTALLINE; MALE; STAINING AND LABELING; TISSUE DONORS;

EID: 84870310603     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2012.10.012     Document Type: Article

References (51)

1. Alafuzoff I., et al. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol. 2008, 115:533-546.
2. Armstrong R.A. Alzheimers's disease and the eye. J. Optom. 2009, 2:103-111.
3. Bachman D.L., et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology 1992, 42:115-119.
4. Bely M., Makovitzky J. Sensitivity and specificity of Congo red staining according to Romhanyi. Comparison with Puchtler's or Bennhold's methods. Acta Histochem. 2006, 108:175-180.
5. Braak H., et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
6. Cobb N.J., et al. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. Proc. Natl. Acad. Sci. U S A 2007, 104:18946-18951.
7. Dickson D.W. Neuropathology of Alzheimer's disease and other dementias. Clin. Geriatr. Med. 2001, 17:209-228.
8. Dutescu R.M., et al. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:1213-1221.
9. Ecroyd H., Carver J.A. Crystallin proteins and amyloid fibrils. Cell. Mol. Life Sci. 2009, 66:62-81.
10. Forman M.S., et al. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004, 10:1055-1063.
11. Frederikse P.H. Amyloid-like protein structure in mammalian ocular lenses. Curr. Eye Res. 2000, 20:462-468.
12. Frederikse P.H., et al. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and abeta has toxic effects on lens epithelial cells. J. Biol. Chem. 1996, 271:10169-10174.
13. Frederikse P.H., Zigler J.S. Presenilin expression in the ocular lens. Curr. Eye Res. 1998, 17:947-952.
14. Frid P., et al. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 2007, 53:135-160.
15. Friedman R. Aggregation of amyloids in a cellular context: modelling and experiment. Biochem. J. 2011, 438:415-426.
16. Goldstein L.E., et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 2003, 361:1258-1265.
17. Gotz J., et al. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 2004, 22:453-465.
18. Hashimoto M., et al. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular. Med. 2003, 4:21-36.
19. Karring H., et al. Composition and proteolytic processing of corneal deposits associated with mutations in the TGFBI gene. Exp. Eye Res. 2012, 96:163-170.
20. Klein B.E., et al. Prevalence of age-related lens opacities in a population. The Beaver Dam eye study. Ophthalmology 1992, 99:546-552.
21. Marsili S., et al. Cataract formation in a strain of rats selected for high oxidative stress. Exp. Eye Res. 2004, 79:595-612.
22. Meehan S., et al. Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. J. Biol. Chem. 2004, 279:3413-3419.
23. Melov S., et al. Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radic. Biol. Med. 2005, 38:258-261.
24. Michael R., et al. Morphology of age-related cuneiform cortical cataracts: the case for mechanical stress. Vis. Res. 2008, 48:626-634.
25. Michael R., Bron A.J. The ageing lens and cataract: a model of normal and pathological ageing. Philos. Trans. R Soc. Lond B Biol. Sci. 2011, 366:1278-1292.
26. Mirra S.S., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
27. Mitchell P., et al. Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology 1997, 104:581-588.
28. Moncaster J.A., et al. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One 2010, 5:e10659.
29. Nishida K., et al. Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies. Br. J. Ophthalmol. 1999, 83:1178-1182.
30. Papanikolopoulou K., et al. Formation of amyloid fibrils in vitro by human gammaD-crystallin and its isolated domains. Mol. Vis. 2008, 14:81-89.
31. Petkova A.T., et al. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 2006, 45:498-512.
32. Petrella J.R., et al. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003, 226:315-336.
33. Philipson B. Distribution of protein within the normal rat lens. Invest. Ophthalmol. 1969, 8:258-270.
34. Prento P. Staining of macromolecules: possible mechanisms and examples. Biotech. Histochem. 2009, 84:139-158.
35. Remtulla S., Hallett P.E. A schematic eye for the mouse, and comparisons with the rat. Vis. Res. 1985, 25:21-31.
36. Romhanyi G. Selective differentiation between amyloid and connective tissue structures based on the collagen specific topo-optical staining reaction with congo red. Virchows Arch. A Pathol. Pathol. Anat. 1971, 354:209-222.
37. Sakaguchi H., et al. Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. J. Neuroinflamm. 2011, 8:116.
38. Sandilands A., et al. Altered aggregation properties of mutant gamma-crystallins cause inherited cataract. EMBO J. 2002, 21:6005-6014.
39. Sasaki H., et al. High prevalence of nuclear cataract in the population of tropical and subtropical areas. Dev. Ophthalmol. 2002, 35:60-69.
40. Shivaprasad S., Wetzel R. Scanning cysteine mutagenesis analysis of Abeta-(1-40) amyloid fibrils. J. Biol. Chem. 2006, 281:993-1000.
41. Sparrow J.M., et al. The Oxford clinical cataract classification and grading system. Int. Ophthalmol. 1986, 9:207-225.
42. Taylor V.L., et al. Morphology of the normal human lens. Invest. Ophthalmol. Vis. Sci. 1996, 37:1396-1410.
43. Truscott R.J. Human age-related cataract: a condition with no appropriate animal model. J. Clin. Exp. Ophthalmol. 2011, 2:1-4.
44. Valenti D.A. Alzheimer's disease: visual system review. Optometry 2010, 81:12-21.
45. van Hout H., et al. Are general practitioners able to accurately diagnose dementia and identify Alzheimer's disease? A comparison with an outpatient memory clinic. Br. J. Gen. Pract. 2000, 50:311-312.
46. Viswanathan A., Greenberg S.M. Cerebral amyloid angiopathy in the elderly. Ann. Neurol. 2011, 70:871-880.
47. Vrensen G., Willekens B. Classification and prevalence of early senile lens opacities in human donor eyes. Dev. Ophthalmol. 1989, 17:181-187.
48. Vrensen G.F. Early cortical lens opacities: a short overview. Acta Ophthalmol. 2009, 87:602-610.
49. Wang Y., et al. Formation of amyloid fibrils in vitro from partially unfolded intermediates of human gammaC-crystallin. Invest. Ophthalmol. Vis. Sci. 2010, 51:672-678.
50. Wenk G.L. Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 2003, 64(Suppl. 9):7-10.
51. Yin Y.I., et al. {gamma}-Secretase substrate concentration modulates the Abeta42/Abeta40 ratio: implications for Alzheimer disease. J. Biol. Chem. 2007, 282:23639-23644.